|
Analytical method development and validation for extraction and quantification of apixaban in human plasma using HPLC
|
Seyed Mohammad Alavi1    , Amir Beheshti Maal1 , Mohsen Amini2 , Hoda Jahandar3 |
1- PharmD Student, Department of Pharmaceutical Chemistry, TMS.C., Islamic Azad University, Tehran, Iran
2- Professor, Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences (TUMS), Tehran, Iran , moamini@tums.ac.ir
3- Assistant professor, Department of Pharmacognosy, TMS.C., Islamic Azad University, Tehran, Iran |
|
|
Abstract: (265 Views) |
Background: Apixaban, an oral anticoagulant and direct factor Xa inhibitor, is used to reduce the risk of various thromboembolic diseases. Measuring the active substance in blood can assess its effectiveness compared to the reference drug. In this study, a rapid, new, and reliable reversed-phase liquid chromatography method was developed for measuring apixaban in human plasma.
Materials and methods: The chromatographic conditions were optimized, followed by validation using spiked standard samples. To evaluate the extraction method of Apixaban from spiked blood samples, the recovery rate was calculated.
Results: The chromatographic analysis was conducted on a C18 column (250 mm × 4.6 mm, 5μ) using isocratic elution with a mobile phase consisting of a mixture of acetonitrile: ammonium acetate buffer 0.15% at pH 7.6 ± 0.05 with a 50:50 volume ratio and a flow rate of 1 mL/min at room temperature. Apixaban detection was carried out at 276 nm. The calibration curve for apixaban in human plasma was linear in the range of 0.3 to 0.12288 µg/ml with a correlation coefficient of r2 = 0.9957. Limit of Quantitation and Limit of Detection concentrations were obtained as 0.06 and 0.02 µg/ml, respectively and the average extraction recovery of the extraction method was 78.73%.
Conclusion: The developed and validated HPLC-UV method presented in the study is suitable for accurate determination of apixaban levels in the pharmacokinetic studies.
|
|
| Keywords: Apixaban, Oral anticoagulant drug, RP-HPLC, Drug quantification, Human plasma. |
|
|
Full-Text [PDF 1305 kb]
(69 Downloads)
|
Semi-pilot: Experimental |
Subject:
Pharmacology
Received: 2024/05/27 | Accepted: 2024/08/5 | Published: 2025/05/31
|
|
|
|
|
|
|
| References |
1. Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet 2015;386:303-10. [ DOI:10.1016/S0140-6736(15)60245-8] 2. Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Rev 2017;31:193-203. [ DOI:10.1016/j.blre.2017.02.001] 3. Garbayo JLM, Castelló IP, Soler MTF, Ribis MP. Hospital admissions for bleeding events associated with treatment with apixaban, dabigatran and rivaroxaban. Eur J Hosp Pharm 2019;26:106-12. [ DOI:10.1136/ejhpharm-2017-001390] 4. Heidbuchel H, Vrijens B. Non-vitamin K antagonist oral anticoagulants (NOAC): considerations on once-vs. twice-daily regimens and their potential impact on medication adherence. Europace 2015;17:1317-8. [ DOI:10.1093/europace/euv124] 5. Rodriguez R, Carrier M, Wells P. Non‐adherence to new oral anticoagulants: a reason for concern during long‐term anticoagulation? J Thromb Haemost 2013;11:390-94. [ DOI:10.1111/jth.12086] 6. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330-93. [ DOI:10.1093/eurheartj/ehy136] 7. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J 2013;11:8. [ DOI:10.1186/1477-9560-11-8] 8. Haque A, Soundharya R, Venu J, Monika ML, Bakshi V. Method development and validation of apixaban using RP-HPLC method and its stress stability studies. International Journal of Chemical and Pharmaceutical Analysis 2017;5. 9. Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet 2019;58:1265-79. [ DOI:10.1007/s40262-019-00775-z] 10. Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs 2016;16:119-27. [ DOI:10.1007/s40256-015-0157-9] 11. Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda‐Garcia R, et al. Apixaban, an oral, direct factor X a inhibitor: Single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 2013;75(2):476-87. [ DOI:10.1111/j.1365-2125.2012.04369.x] 12. Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor X a inhibitor, in healthy subjects. Br J Clin Pharmacol 2013;76:776-86. [ DOI:10.1111/bcp.12106] 13. Frost C, Shenker A, Jhee S, Yu Z, Wang J, Bragat A, et al. Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. Clin Pharmacol 2018;10:153-63. [ DOI:10.2147/CPAA.S169505] 14. Parys W, Dołowy M, Pyka-Pająk A. Significance of chromatographic techniques in pharmaceutical analysis. Processes 2022;10:172. [ DOI:10.3390/pr10010172] 15. Kazakevich YV, Lobrutto R, eds. HPLC for pharmaceutical scientists. Hoboken, New Jersey, United States: John Wiley & Sons; 2007. [ DOI:10.1002/0470087951] 16. Dzudovic J, Sakac MC, Antunovic M, Repic A, Obradovic S, Djordjevic S, Savic J, Dzudovic B. Development and validation of LC-MS/MS method for determination of plasma apixaban. Acta Chromatographica 2021;34:332-37. [ DOI:10.1556/1326.2021.00948] 17. Lagoutte-Renosi J, Le Poupon J, Girard A, Montange D, Davani S. A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2018;1100-1101:43-49. [ DOI:10.1016/j.jchromb.2018.09.026] 18. Baig ML, Ali SA. A validated LC-MS/MS method for the estimation of apixaban in human plasma. Journal of Applied Pharmaceutical Science 2017;7:044-52. [ DOI:10.1080/22297928.2017.1333039] 19. Landge SB, Jadhav SA, Dahale SB, Solanki PV, Bembalkar SR, Mathad VT. Development and validation of stability indicating RP-HPLC method on core shell column for determination of degradation and process related impurities of apixaban-an anticoagulant drug. American Journal of Analytical Chemistry 2015;6:539-50. [ DOI:10.4236/ajac.2015.66052] 20. Al-Ani I, Hamad M, Al-Shdefat R, Mansoor K, Glogor F, Dayyish WA. Development and validation of stability indicating RP-HPLC method of apixaban in commercial dosage forms. International Journal of Pharmaceutical Sciences and Research 2019;12:241-51. 21. Kashid AM, Vidhate MB, Ingale MR. Analytical method development and validation for estimation of apixaban by RP-HPLC. Indian Drugs 2017;54:76-79. [ DOI:10.53879/id.54.04.10680] 22. Akbel E, Bulduk İ, Gökçe S. A green HPLC method for the determination of apixaban in pharmaceutical products: Development and validation. Reviews in Analytical Chemistry 2023;42:20230058. [ DOI:10.1515/revac-2023-0058] |
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Alavi S M, Beheshti Maal A, Amini M, Jahandar H. Analytical method development and validation for extraction and quantification of apixaban in human plasma using HPLC. MEDICAL SCIENCES 2025; 35 (2) :156-165 URL: http://tmuj.iautmu.ac.ir/article-1-2217-en.html
|
